Pfizer Reports Results From Phase 3 Study Of Torisel (temsirolimus) In Combination With Bevacizumab In Advanced Renal …

Pfizer Inc. announced today that the Phase 3 INTORACT trial , evaluating the combination of bevacizumab plus TORISEL® compared with bevacizumab plus interferon-alfa-2a in the first-line treatment of patients with advanced renal cell carcinoma across risk groups, did not meet its primary endpoint of superiority in extending progression free survival in the study population.

Powered by WPeMatico